A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 22 Jul 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 22 Jul 2011 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Actual initiation date changed from 9 Nov 2006 to Aug 2006, additional trial location (USA) identified and company added (Salix Pharmaceuticals) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top